Note 18 - Segment Information (Tables)

6 Months Ended

Jun. 30, 2026

Notes Tables

Segment Reporting [Table Text Block]

	As of June 30, 2026						As of December 31, 2025
	Biopharma		CDMO		Consolidated		Biopharma		CDMO		Consolidated
Cash and cash equivalents	$	1,991	$	117	$	2,108	$	12,277	$	368	$	12,645
Inventory, net		750	$	—	$	750		—	$	—	$	—
Prepaid expenses and other current assets		78		446		524		156		190		346
Property and equipment, net		26		12,317		12,343		34		12,607		12,641
Deferred offering costs		631		—		631		136		—		136
Licensed technology, net		2,243		—		2,243		2,243		—		2,243
Operating lease right-of-use assets, net		—		9,835		9,835		—		—		—
Goodwill		—		3,457		3,457		—		3,457		3,457
Restricted cash		368		—		368		—		—		—
Other assets		130		84		214		124		—		124
Total consolidated assets of continuing operations	$	6,217	$	26,256	$	32,473	$	14,970	$	16,622	$	31,592

	Three Months Ended June30, 2026									Three Months Ended June 30, 2025
	Biopharma			CDMO			Consolidated			Biopharma			CDMO		Consolidated
Operating Expenses
Research and development	$	1,544		$	1,160		$	2,704		$	655		$	—	$	655
Selling, general and administrative		1,431			2,289			3,720			1,023			—		1,023
Total operating expenses		2,975			3,449			6,424			1,678			—		1,678
Other expense (income)
Change in fair value of derivative liability		47			—			47			—			—		—
Interest income		11			—			11			3			—		3
Interest expense		(691	)		—			(691	)		—			—		—
Net other (expense) income		(633	)		—			(633	)		3			—		3
Net loss from operations before discontinued operations	$	(3,608	)	$	(3,449	)	$	(7,057	)	$	(1,675	)	$	—	$	(1,675	)
	Six Months Ended June 30, 2026									Six Months Ended June 30, 2025
	Biopharma			CDMO			Consolidated			Biopharma			CDMO		Consolidated
Operating Expenses
Research and development	$	2,401		$	2,157		$	4,558		$	990		$	—	$	990
Selling, general and administrative		3,485			4,015			7,500			2,065			—		2,065
Total operating expenses		5,886			6,172			12,058			3,055			—		3,055
Other expense (income)
Change in fair value of derivative liability		80			—			80			—			—		—
Interest income		35			—			35			7			—		7
Interest expense		(1,339	)		—			(1,339	)		—			—		—
Net other (expense) income		(1,224	)		—			(1,224	)		7			—		7
Net loss from operations before discontinued operations	$	(7,110	)	$	(6,172	)	$	(13,282	)	$	(3,048	)	$	—	$	(3,048	)